News stories about Esperion Therapeutics (NASDAQ:ESPR) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Esperion Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.6506775138168 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at $74.92 on Tuesday. The company has a market cap of $1,962.73, a PE ratio of -10.91 and a beta of 2.64. Esperion Therapeutics has a one year low of $20.39 and a one year high of $82.18.
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.36. During the same quarter in the previous year, the firm posted ($1.29) EPS. analysts anticipate that Esperion Therapeutics will post -7.3 earnings per share for the current fiscal year.
A number of research analysts have weighed in on the stock. Citigroup cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $77.00 to $96.00 in a report on Monday, January 22nd. Stifel Nicolaus set a $105.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Monday, January 15th. BidaskClub raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 13th. Credit Suisse Group assumed coverage on shares of Esperion Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 price objective for the company. Finally, UBS Group set a $88.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $77.23.
In related news, Director Nicole Vitullo sold 11,674 shares of the business’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the transaction, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 32.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics (NASDAQ:ESPR) Receiving Somewhat Favorable News Coverage, Study Finds” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/20/esperion-therapeutics-espr-given-news-impact-score-of-0-21.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.